Collegium Pharmaceutical
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Massachusetts, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
100 Technology Center Dr, Stoughton, Mas...Phone Number
(781) 713-3699Website
www.collegiumpharma.comRevenue
$796.3 MillionStock Symbol
COLLIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
4
5
1
1
1
1
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.Explore more
Collegium Pharmaceutical Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Collegium Pharmaceutical your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Collegium Pharmaceutical has recently received funding, and reach out quickly before it becomes old news!
Click to see if Collegium Pharmaceutical had a recent Job posting/layoffs
Check out if Collegium Pharmaceutical is spiking on competitors!
Earning: See what the market has to say on Collegium Pharmaceutical recently announced quarterly report
Product Launch: Get notified when Collegium Pharmaceutical launches new products
Funding: Get notified immidiatlly once Collegium Pharmaceutical has new funding data
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Collegium Pharmaceutical
Collegium Pharmaceutical, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Collegium Pharmaceutical
Find more new buyers
Compare Similar Companies to Collegium Pharmaceutical
Compare insights from companies similar to Collegium Pharmaceutical, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Collegium Pharmaceutical is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Collegium Pharmaceutical is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Collegium Pharmaceutical.
Collegium Pharmaceutical financials insights
Gather financial insights about Collegium Pharmaceutical, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2010
Debt
$1M
2012
Series B
$22.5M
2013
Private Equity
$4M
2015
Other Financing Round
$50M
Stock Offering
$69.6M
2016
Stock Offering
$55M
Stock Offering
$80M
2020
Stock Offering
$125M
2022
Debt
$650M
Collegium Pharmaceutical Tech Stack
A closer look at the technologies used by Collegium Pharmaceutical
See more technologies
Most Recent Scoops
Person-Based
Sales, Business Development, Marketing Strategy
Person-Based
Earnings, Pharmaceuticals, Finance
Open Position
Person-Based
Earnings, Finance
Person-Based
Earnings, Pharmaceuticals, Corporate Strategy, Finance
Collegium Pharmaceutical News & Media
Interested in Collegium Pharmaceutical Inc (COLL) Stock? Look at ADHD Portfolio
Collegium Pharmaceutical Inc (NASDAQ:COLL) is one of the best micro and small cap stocks to buy according to Jim Simons’ Renaissance Technologies. Analysts expect the stock to gain 57% over the next 12 months. On May 7, Collegium Pharmaceutical Inc (NASDAQ:COLL) reported Q1 2026 results that both increased from the prior year and exceeded the […]Collegium to Participate in 2026 Jefferies Global Healthcare Conference
STOUGHTON, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference.Collegium Completes Acquisition of AZSTARYS® from Corium Therapeutics
– Adds Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium’s Existing ADHD Portfolio –Collegium Reports First Quarter 2026 Financial Results and Highlights Recent Company Progress
– Generated Quarterly Net Revenues of $193.5 Million, Up 9% Year-over-Year –
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Collegium Pharmaceutical
Sign Up For FreeTo access detailed company insights
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioi... Read More
